Recent patents on experimental therapy for hepatitis C virus infection (1999 - 2002)

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 11, 2003, Pages 1707-1723

  Hoffmann, Per ^a   Quasdorff, Maria ^a   González Carmona, María Á ^a   Caselmann, Wolfgang H ^b  

^a UNIVERSITY OF BONN   (Germany)

^b Health and Consumer Protection   (Germany)

Author keywords

Aptamers; Chemicals; Fusion DNA; Fusion proteins; Helicase inhibitor; Hepatitis C virus (HCV); Immunotherapy; Inosine monophosphate dehydrogenase (IMPDH) inhibitor; Nucleoside analogues; Oligodeoxynucleotides; Peptides; Peptidomimetics; Polymerase inhibitor; Protease inhibitor; Ribozymes

Indexed keywords

(5 PHENYL[1,2,4]THIADIAZOL 3 YL)THIOUREA; 5 (DICHLOROPHENYLMETHYLENE) 3 (METHANESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 AMINO 2 (4 CHLOROPHENYL) 3 PHENYL[1,2,4]THIADIAZOL 2 IUM CHLORIDE; ALPHA INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTIVIRUS AGENT; BETA DEXTRO N4 HYDROXYCYTIDINE; GLUTATHIONE DERIVATIVE; HELICASE; IMMUNOMODULATING AGENT; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; INTERFERON; LEVOVIRIN; NUCLEOSIDE ANALOG; PRODRUG; PROTEINASE INHIBITOR; PURINE NUCLEOSIDE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; PYRIMIDINONE DERIVATIVE; RIBAMIDINE; RIBAVIRIN; RIBOZYME; RNA HELICASE; SERINE PROTEINASE INHIBITOR; THIAZOLIDINE DERIVATIVE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VP 50406;

ADENOVIRUS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG SPECIFICITY; ERADICATION THERAPY; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS C VIRUS; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; LEUKOPENIA; NEUROPATHOLOGY; NONHUMAN; PATENT; PROTEINASE INHIBITION; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TOXICITY TESTING; VIRUS RECOMBINANT;

EID: 0242558929     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.11.1707     Document Type: Review

References (140)

1. ALTER HJ: Discovery of the non-A, non-B hepatitis virus: the end of the beginning or the beginning of the end. Transfus. Med. Rev. (1989) 3(2):77-81.
2. KUO G, CHOO QL, ALTER HJ et al.: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 244(4902):362-364.
3. ALBERTI A, BENVEGNU L: Management of hepatitis C. J. Hepatol. (2003) 38(Suppl.1):S104-S118.
4. WALKER MA: Hepatitis C virus: an overview of current approaches and progress. Drug Discov. Today (1999) 4(11):518-529.
5. GIANNINI C, BRECHOT C: Hepatitis C virus biology. Cell Death Differ (2003) 10(Suppl.1):S27-S38.
6. NAOUMOV NV, CHOKSHI S, METIVIER E, MAERTENS G, JOHNSON PJ, WILLIAMS R: Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. J. Hepatol. (1997) 27(2):331-336.
7. SAITO I, MIYAMURA T, OHBAYASHI A et al.: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA (1990) 87(17):6547-6549.
8. CASELMANN WH, ALT M: Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. J. Hepatol. (1996) 24(2):61-66.
9. TSAI JF, JENG JE, HO MS et al.: Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br. J. Cancer (1997) 76(7):968-974.
10. SERFATY L, AUMAITRE H, CHAZOUILLERES O et al.: Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 27(5):1435-1440.
11. ALTER MJ, MAST EE, MOYER LA, MARGOLIS HS: Hepatitis C. Infect. Dis. Clin. North Am. (1998) 12(1):13-26.
12. NISHIOKA K: Epidemiological studies on hepatitis C virus infection: detection, prevalence, exposure and prevention. Intervirology (1994) 37(2):58-67.
13. ZEUZEM S, TEUBER G, LEE JH, RUSTER B, ROTH WK: Risk factors for the transmission of hepatitis C. J. Hepatol. (1996) 24(2):3-10.
14. HOOFNAGLE JH: Course and outcome of hepatitis C. Hepatology (2002) 36(5Suppl.1):S21-S29.
15. FATTOVICH G, RIBERO ML, PANTALENA M et al.: Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J. Viral Hepat. (2001) 8(3):206-216.
16. BRECHOT C: Hepatitis C virus: molecular biology and generic variability. Dig. Dis. Sci. (1996) 41(12Suppl.):6S-S21.
17. ROFFI L, REDAELLI A, COLLOREDO G et al.: Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur. J. Gastroenterol. Hepatol. (2001) 13(5):501-506.
18. ZEIN NN: Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. (2000) 13(2):223-235.
19. FARCI P, PURCELL RH: Clinical significance of hepatitis C virus genotypes and quasispecies. Semin. Liver Dis. (2000) 20(1):103-126.
20. MIYAKAWA Y, OKAMOTO H, MAYUMI M: Classifying hepatitis C virus genotypes. Mol. Med. Today (1995) 1(1):20-25.
21. BUKH J, PURCELL RH, MILLER RH: At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Prac. Natl. Acad. Sci. USA (1993) 90(17):8234-8238.
22. HIJIKATA M, KATO N, OOTSUYAMAY, ENAKAGAWA M, SHIMOTOHNO K: Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. USA (1991) 88(13):5547-5551.
23. CHOO QL, RICHMAN KH, HAN JH et al.: Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA (1991) 88(6):2451-2455.
24. HOUGHTON M, WEINER A, HAN J, KUO G, CHOO QL: Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology (1991) 14(2):381-388.
25. DE FRANCESCO R: Molecular virology of the hepatitis C virus. J. Hepatol. (1999) 31(Suppl.1):47-53.
26. SUZUKI R, SUZUKI T, ISHII K, MATSUURA Y, MIYAMURA T: Processing and functions of hepatitis C virus proteins. Intervirology (1999) 42(2-3):145-152.
27. YAN Y, LI Y, MUNSHI S et al.: Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form. Protein Sci. (1998) 7(4):837-847.
28. KIM JL, MORGENSTERN KA, GRIFFITH JP et al.: Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure (1998) 6(1):89-100.
29. TAI CL, PAN WC, LIAW SH YANG UC, HWANG LH, CHEN DS: Structure-based mutational analysis of the hepatitis C virus NS3 helicase. J. Virol. (2001) 75(17):8289-8297.
30. KANG LW, CHO HS, CHA SS et al.: Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein. Acta. Crystallogr. D Biol. Crystallogr. (1998) 54(Pt1):121-123.
31. DI MARCO S, RIZZI M, VOLPARI C et al.: Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J. Biol. Chem. (2000) 275(10):7152-7157.
32. BARTENSCHLAGER R. The NS3/4A protease of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J. Viral Hepat. (1999) 6(3):165-181.
33. KIM JL, MORGENSTERN KA, LIN C et al.: Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell (1996) 87(2):343-355.
34. BRESSANELLI S, TOMEI L, ROUSSEL A et al.: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA (1999) 96(23):13034-13039.
35. LESBURG CA, CABLE MB, FERRARI E, HONG Z, MANNARINO AF, WEBER PC: Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct. Biol. (1999) 6(10):937-943.
36. QIN W, YAMASHITA T, SHIROTA Y, LIN Y, WEI W, MURAKAMI S: Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology (2001) 33(3):728-737.
37. BOROWSKI P, SCHALINSKI S, SCHMITZ H: Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res. (2002) 55(3):397-412.
38. LOCARNINI SA, BARTHOLOMEUSZ A: Advances in hepatitis C: what is coming in the next 5 years? J. Gastroenterol. Hepatol. (2002) 17(4):442-447.
39. DI BISCEGLIE AM, MCHUTCHISON J, RICE CM: New therapeutic strategies for hepatitis C. Hepatology (2002) 35(1):224-231.
40. GRAKOUI A, MCCOURT DW, WYCHOWSKI C, FEINSTONE SM, RICE CM: A second hepatitis C virus-encoded protease. Proc. Natl. Acad. Sci. USA (1993) 90(22):10583-10587.
41. DARKE PL, JACOBS AP, WAXMAN L, KUO LC: Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides. Implications for control of viral processing. J. Biol. Chem. (1999) 274(49):34511-34514.
42. REYES GR: The non-structural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J. Biomed. Sci. (2002) 9(3):187-197.
43. GALE MJ Jr, KORTH MJ, KATZE MG: Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin. Diagn. Virol. (1998) 10(2-3):157-162.
44. GIRARD S, SHALHOUB P, LESCURE P et al.: An altered cellular response to interferon and upregulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology (2002) 295(2):272-283.
45. CROTTY S, MAAG D, ARNOLD JJ et al.: The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. (2000) 6(12):1375-1379.
46. MAAG D, CASTRO C, HONG Z et al.: Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. (2001) 276(49):46094-46098.
47. KIEFF JS, ZHOU K, GRECH A et al.: Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. Nat. Struct. Biol. (2002) 9(5):370-374.
48. RIJNBRAND RC, LEMON SM: Internal ribosome entry site-mediated translation in hepatitis C virus replication. Curr. Top. Microbiol. Immunol. (2000) 242:85-116.
49. HONDA M, BROWN EA, LEMON SM: Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. RNA (1996) 2(10):955-968.
50. HONDA M, PING LH, RIJNBRAND RC et al.: Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology (1996) 222(1):31-42.
51. YAMADA N, TANIHARA K, TAKADA A et al.: Genetic organization and diversity of the 3′ non-coding region of the hepatitis C virus genome. Virology (1996) 223(1):255-261.
52. ALT M, RENZ R, HOFSCHNEIDER PH, PAUMGARTNER G, CASELMANN WH: Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology (1995) 22(3):707-717.
53. ALT M, EISENHARDT S, SERWE M, RENZ R, ENGELS JW, CASELMANN WH: Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation. Eur. J. Clin. Invest. (1999) 29(10):868-876.
54. GALLEGO J, VARANI G: The hepatitis C virus internal ribosome-entry site: a new target for antiviral research. Biochem. Soc. Trans. (2002) 30(2):140-145.
55. CHRISTIE JM, CHAPEL H, CHAPMAN RW, ROSENBERG WM: Immune selection and generic sequence variation in core and envelope regions of hepatitis C virus. Hepatology (1999) 30(4):1037-1044.
56. BUKH J, FORNS X, EMERSON SU, PURCELL RH: Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology (2001) 44(2-3):132-142.
57. BEARD MR, ABELL G, HONDA M et al.: An infectious molecular done of a Japanese genotype 1b hepatitis C virus. Hepatology (1999) 30(1):316-324.
58. KOLYKHALOV AA, AGAPOV EV, BLIGHT KJ, MIHALIK K, FEINSTONE SM, RICE CM: Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 277(5325):570-574.
59. YANAGI M, PURCELL RH, EMERSON SU, BUKH J: Transcripts from a single full-length cDNA done of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. USA (1997) 94(16):8738-8743.
60. BARTENSCHLAGER R, LOHMANN V: Novel cell culture systems for the hepatitis C virus. Antiviral Res. (2001) 52(1):1-17.
61. BARTENSCHLAGER R, LOHMANN V: Replication of the hepatitis C virus. Baillieres Best Pract. Res. Clin. Gastroenterol. (2000) 14(2):241-254.
62. LOHMANN V, KORNER F, KOCH J, HERIAN U, THEILMANN L, BARTENSCHLAGER R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285(5424):110-113.
63. BRONOWICKI JP, LORIOT MA, THIERS V, GRIGNON Y, ZIGNEGO AL, BRECHOT C: Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology (1998) 28(1):211-218.
64. BLINDENBACHER A, DUONG FH, HUNZIKER L et al.: Expression of hepatitis C virus proteins inhibits interferon-α signalling in the liver of transgenic mice. Gastroenterology (2003) 124(5):1465-1475.
65. KAWAMURA T, FURUSAKA A, KOZIEL MJ et al.: Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology (1997) 25(4):1014-1021.
66. FAUSTO N: A mouse model for hepatitis C virus infection? Nat. Med. (2001) 7(8):890-891.
67. DI BISCEGLIE AM, HOOFNAGLE JH: Optimal therapy of hepatitis C. Hepatology (2002) 36(5Suppl.1):S121-S127.
68. MANNS MP, CORNBERG M, WEDEMEYER H: Current and future treatment of hepatitis C. Indian J. Gastroenterol. (2001) 20(Suppl.1)C47-C51.
69. MCHUTCHISON JG, PATEL K: Future therapy of hepatitis C. Hepatology (2002) 36(5 Suppl-1):S245-S252.
70. SIEVERT W: Management issues in chronic viral hepatitis: hepatitis C. J. Gastroenterol. Hepatol. (2002) 17(4):415-422.
71. LAU JY, TAM RC, LIANG TJ, HONG Z: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 35(5):1002-1009.
72. ZHOU S, LIU R, RAROUDY BM, MALCOLM BA, REYES GR: The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology (2003) 310(2):333-342.
73. LIN CC, LUU K, LOURENCO D, YEH LT: Viramidine, a prodrug of ribavirin, demonstrated superior liver-targeting properties and much improved toxicity profile in cynomolgus monkey studies. Hepatology (2001) 34(Suppl.):453a. Abstract.
74. YEH L, FANG JW, NGUYEN M et al.: Determination of viramidine/ribavirin in human RBC following single oral dosing of viramidine in a Phase I Study. Hepatology (2002) 36(4):345A.
75. STUYVER LJ, WHITAKER T, MCBRAYER TR et al.: Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. (2003) 47(1):244-254.
76. BEAULIEU PL, LLINAS-BRUNET M: Therapies for hepatitis C infection: targeting the non-structural proteins of HCV. Curr Med. Chem. (2002) 1:163-176.
77. MYLES DC: Recent advances in the discovery of small molecule therapies for HCV. Curr. Opin. Drug Discov. Devel. (2001) 4(4):411-416.
78. NARJES F, KOCH U, STEINKUHLER C: Recent developments in the discovery of hepatitis C virus serine protease inhibitors - towards a new class of antiviral agents? Expert Opin. Investig. Drugs. (2003) 12(2):153-163.
79. JAIN A, KASHYAP R, DEMETRIS AJ, EGHSTESAD B, POKHARNA R, FUNG JJ: A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl. (2002) 8(1):40-46.
80. FIRPI RJ, NELSON DP, DAVIS GL: Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl. (2003) 9(1):57-61.
81. CORNBERG M, HINRICHSEN H, TEUBER G et al.: Mycophenolate mofetil in combination with recombinant interferon-α-2a in interferon-nonresponder patients with chronic hepatitis C. J. Hepatol. (2002) 37(6):843-847.
82. MARKLAND W, MCQUAID TJ, JAIN J, KWONG AD: Broad spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with a interferon. Antimicrob. Agents Chemother. (2000) 44(4):859-866.
83. TAN SL, PAUSE A, SHI Y, SONENBERG N: Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discov. (2002) 1(11):867-881.
84. DYMOCK BW: Emerging therapies for hepatitis C virus infection. Emerging Drugs (2001) 6(1):13-42.
85. WAXMAN L, WHITNEY M, POLLOK BA, KUO LC, DARKE PL: Host cell factor requirement for hepatitis C virus enzyme maturation. Proc. Natl. Acad. Sci. USA (2001) 98(24):13931-13935.
86. SCHEIBEL T, BUCHNER J: The Hsp90 complex - a super-chaperone machine as a novel drug target. Biochem. Pharmacol. (1998) 56(6):675-682.
87. PIPER PW: The Hsp90 chaperone as a promising drug target. Curr. Opin. Investig. Drugs (2001) 2(11):1606-1610.
88. MIYATA Y: [Molecular chaperone Hsp90 as a novel target for cancer chemotherapy]. Nippon Yakurigaku Zasshi (2003) 121(1):33-42. Japanese.
89. JOHNSON BD, CHADLI A, FELTS SJ, BOUHOUCHE I, CATELLI MG, TOFT DO: Hsp90 chaperone activity requires the full-length protein and interaction among its multiple domains. J. Biol. Chem. (2000) 275(42):32499-32507.
90. ANDRE P, GROETTRUP M, KLENERMAN P et al.: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation and T cell responses. Proc. Natl. Acad. Sci. USA (1998) 95(22):13120-13124.
91. FIALAIRE P, PAYAN C, VITOUR D et al.: Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J. Infect. Dis. (1999) 180(2):574-575.
92. JOHN M, FLEXMAN J, FRENCH MA: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? Aids (1998) 12(17):2289-2293.
93. MATSIOTA-BERNARD P, VRIONI G, ONODY C, BERNARD L, DE TRUCHIS P, PERONNE C: Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. Int. J. Antimicrob. Agents (2001) 17(2):155-157.
94. COOPER CL, PARBHAKAR MA, ANGEL JB: Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin. Infect. Dis. (2002) 34(9):1259-1263.
95. SAVES M, RAFFI F, CLEVENBERGH P et al.: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob. Agents Chemother. (2000) 44(12):3451-3455.
96. SCHANG LM: Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. (2002) 50(6):779-792.
97. SCHANG LM, BANTLY A, KNOCKAERT M et al.: Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus Type 1 by targeting cellular, not viral, proteins. J. Virol. (2002) 76(15):7874-7882.
98. WANG QM, HEINZ BA: Recent advances in prevention and treatment of hepatitis C virus infections. Prog. Drug Res. (2000) 55:1-32.
99. KEE KS, JOIS SD: Design of β-turn based therapeutic agents. Curr. Pharm. Des. (2003) 9(15):1209-1224.
100. THIBEAULT D, MAURICE R, PILOTE L et al.: In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J. Biol. Chem. (2001) 276(49):46678-46684.
101. SULKOWSKI MS: Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin. Liver Dis. (2003) 23(2):183-194.
102. INGALLINELLA P, FATTORI D, ALTAMURA S et al.: Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry (2002) 41(17):5483-5492.
103. LAMARRE D, BAILEY M, BOLGER G et al.: The discovery of BILN-2061 - an orally bioavailable small molecule inhibitor of the HCV serine protease and a promising antiviral for the treatment of hepatits C. Hepatology (2002) 36(4):279A
104. BRANCH AD: A hitchhiker's guide to antisense and non-antisense biochemical pathways. Hepatology (1996) 24(6):1517-1529.
105. CASELMANN WH, SERWE M, LEHMANN T et al.: Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C virus gene expression in vitro and in vivo. World J. Gastroenterol. (2000) 6(5):626-629.
106. LEHMANN TJ, SERWE M, CASELMANN WH et al.: Design and properties of hepatitis C virus antisense oligonucleotides for liver specific drug targeting. Nucleosides Nucleotides Nucleic Acids (2001) 20(4-7):1343-1346.
107. TALLET-LOPEZ B, ALDAZ-CARROLL L, CHABAS S, DAUSSE E, STAEDEL C, TOULME JJ: Antisense oligonucleotides targeted to the domain IIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation. Nucleic Acids Res. (2003) 31(2):734-742.
108. TESSMANN K, ERHARDT A, HAUSSINGER D et al.: Cloning and molecular characterization of human high affinity antibody fragments against hepatitis C virus NS3 helicase. J. Virol. Methods (2002) 103(1):75-88.
109. HEINTGES T, ENCKE J, ZU PUTLITZ J et al.: Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J. Med. Virol. (2001) 65(4):671-680.
110. IMANISHI T, OBIKA S: [Downregulation of a gene-expression by an antisense BNA oligonucleotide]. Nippon Yakurigaku Zasshi (2002) 120(2):85-90. Japanese.
111. ZHANG H, HANECAK R, BROWN-DRIVER V et al.: Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother. (1999) 43(2):347-353.
112. MACEJAK DG, JENSEN K L, PAVCO PA et al.: Enhanced antiviral effect in cell culture of Type 1 interferon and ribozymes targeting HCV RNA. J. Viral Hepat. (2001) 8(6):400-405.
113. LEE PA, BLATT LM, BLANCHARD KS et al.: Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology (2000) 32(3):640-646.
114. OSTENDORF T, FLOEGE J: Aptamers: a novel approach to intervention studies and development of novel therapeutic approaches. Med. Klin. (1999) 94(4):219-223.
115. JAYASENA SD: Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. (1999) 45(9):1628-1650.
116. GORDON SC, BACON BR, JACOBSON IM et al.: A Phase II 12-week study of ISIS-14803, an antisense inhibitor of HCV for the treatment of chronic hepatitis C. Hepatology (2002) 36(4):362A.
117. TONG M, SCHIFF E, JENSEN DM et al.: Preliminary analysis of a Phase II study of heptazyme nuclease-resistent ribozyme targeting hepatitis C virus (HCV) RNA. Hepatology (2002) 36(4):360A.
118. VO NV, OH JW, LAI MM: Identification of RNA ligands that bind hepatitis C virus polymerase selectively and inhibit its RNA synthesis from the natural viral RNA templates. Virology (2003) 307(2):301-316.
119. NISHIKAWA F, KAKIUCHI N, FUNAJI K, FUKUDA K, SEKIYA S, NISHIKAWA S: Inhibition of HCV NS3 protease by RNA aptamers in cells. Nucleic Acids Res. (2003) 31(7):1935-1943.
120. JAASKELAINEN I, URTTI A: Cell membranes as barriers for the use of antisense therapeutic agents. Mini Rev. Med. Chem. (2002) 2(4):307-318.
121. AURISICCHIO L, BUJARD H, HILLEN W et al.: Regulated and prolonged expression of mIFN-α in immunocompetent mice mediated by a helper-dependent adenovirus vector. Gene Ther. (2001) 8(24):1817-1825.
122. PARKS RJ, CHEN L, ANTON M, SANKAR U, RUDNICKI MA, GRAHAM FL: A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA (1996) 93(24):13565-13570.
123. GRACIE JA, ROBERTSON SE, MCINNES IB: Interleukin-18. J. Leukoc, Biol. (2003) 73(2):213-224.
124. LOUIS H, VAN LAETHEM JL, WU W et al.: Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation and liver fibrosis induced by carbon tetrachloride in mice. Hepatology (1998) 28(6):1607-1615.
125. THOMPSON KC, TROWERN A, FOWELL A et al.: Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation In vitro. Hepatalogy (1998) 28(6):1518-1524.
126. THOMPSON K, MALTBY J, FALLOWFIELD J, MCAULAY M, MILLWARD-SADLER H, SHERON N: Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology (1998) 28(6):1597-1606.
127. ZEKRY A, BISHOP GA, BOWEN DG et al.: Intrahepatic cytokine profiles associated with post-transplantation hepatitis C virus-related liver injury. Liver Transpl. (2002) 8(3):292-301.
128. MCHUTCHISON JG, GIANNELLI G, NYBERG L et al.: A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J. Interferon Cytokine Res. (1999) 19(11):1265-1270.
129. STEINMAN RM: The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. (1991) 9:271-296.
130. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252.
131. ROMANI N, GRUNER S, BRANG D et al.: Proliferating dendritic cell progenitors in human blood. J. Exp. Med. (1994) 180(1):83-93.
132. NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat. Med. (1998) 4(3):328-332.
133. WAN Y, BRAMSON J, CARTER R, GRAHAM F, GAULDIE J: Dendritic cells transduced with an adenoviral vector encoding a model tumour-associated antigen for tumour vaccination. Hum. Gene Ther. (1997) 8(11):1355-1363.
134. HOMMA S, TODA G, GONG J, KUFE D, OHNO T: Preventive antitumour activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. Gastroenterol (2001) 36(11):764-771.
135. ITO A, KANTO T, KUZUSHITA N et al.: Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic: cells. J. Gastroenterol. Hepatol. (2001) 16(3):309-316.
136. MATSUI M, MORIYA O, ABDEL-AZIZ N et al.: Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine (2002) 21(3-4):211-220.
137. BAIN C, FATMI A, ZOULIM F et al.: Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 120(2):512-524.
138. + T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J. Virol. (2002) 76(10):5062-5070.
139. POYNARD T, MARCELLIN P, LEE SS et al.: Randomised trial of interferon-α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (1998) 352(9138):1426-1432.
140. MCHUTCHISON JG, GORDON SC, SCHIFF ER et al.: Interferon-α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. (1998) 339(21):1485-1492.